Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment
Open Access
- 1 October 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 23 (10), 1591-1600
- https://doi.org/10.1359/jbmr.080506
Abstract
Previous antiresorptive (AR) treatment may influence the response to teriparatide. We examined BMD response and safety in a subgroup of 503 postmenopausal women with osteoporosis who received teriparatide for 24 mo. Patients were divided into three groups based on their prior AR treatment: treatment‐naïve (n = 84); pretreated with no evidence of inadequate treatment response (n = 134); and pretreated showing an inadequate response to AR treatment (n = 285), which was predefined based on the occurrence of fractures, persistent low BMD, and/or significant BMD loss while on therapy. Changes in BMD from baseline were analyzed using mixed model repeated measures. Lumbar spine BMD increased significantly from baseline at 6, 12, 18, and 24 mo in all three groups. The mean gain in spine BMD over 24 mo was greater in the treatment‐naïve group (0.095 g/cm2; 13.1%) than in the AR pretreated (0.074 g/cm2; 10.2%; p < 0.005) and inadequate AR responder (0.071 g/cm2; 9.8%; p < 0.001) groups. The corresponding increases in total hip BMD were 3.8%, 2.3%, and 2.3%, respectively. Early decreases in hip BMD in the inadequate AR responder group were reversed by 18 mo of treatment. Increases in BMD between 18 and 24 mo were highly significant. Nausea (13.3%) and arthralgia (11.7%) were the most commonly reported adverse events. Asymptomatic hypercalcemia was reported in 5.0% of patients. Teriparatide treatment for 24 mo is associated with a significant increase in BMD in patients with and without previous AR use. Prior AR treatment modestly blunted the BMD response to teriparatide. Safety was consistent with current prescribing label information.Keywords
This publication has 27 references indexed in Scilit:
- Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women With OsteoporosisJournal of Bone and Mineral Research, 2007
- Skeletal actions of intermittent parathyroid hormone: Effects on bone remodelling and structureBone, 2006
- Effects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic MenJournal of Clinical Endocrinology & Metabolism, 2006
- Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its UseEndocrine Reviews, 2005
- Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or AlendronateJournal of Bone and Mineral Research, 2004
- Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone StructureJournal of Bone and Mineral Research, 2003
- The Effects of Parathyroid Hormone, Alendronate, or Both in Men with OsteoporosisNew England Journal of Medicine, 2003
- New Bone Formation with Teriparatide [Human Parathyroid Hormone-(1–34)] Is Not Retarded by Long-Term Pretreatment with Alendronate, Estrogen, or Raloxifene in Ovariectomized RatsEndocrinology, 2003
- Effects of Daily Treatment with Parathyroid Hormone on Bone Microarchitecture and Turnover in Patients with Osteoporosis: A Paired Biopsy StudyJournal of Bone and Mineral Research, 2001
- Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2001